BioTuesdays

Category - Markets

IRIDEX
Markets

Roth resumes coverage of IRIDEX at buy, PT $13

Roth Capital Partners resumed coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $13 price target after the company reported modest upside to Roth’s prior revenue targets for the third quarter. “Further, the...

November 3, 2017
Syros-Logo
Markets

Roth starts Syros at neutral, PT $16

Roth Capital Partners launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “neutral” rating and price target of $16. The stock closed at $16.51 on Oct.23. “Syros is maturing into a solid company, but value...

October 24, 2017
Markets

Roth resumes coverage of Actinium at buy, PT $6

Roth Capital Partners resumed coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with a “buy” rating and price target of $6.  The stock closed at 73 cents on Oct.23. Analyst Jotin Marango writes that Actinium...

October 24, 2017
GlycoMimetics
Markets

Roth starts GlycoMimetics at buy, PT $25

Roth Capital Partners initiated coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and $25 price target. The stock closed at $10.52 on Oct. 23. “Our bull thesis on GlycoMimetics is driven by the GMI-1271...

October 24, 2017
Appili Therapeutics
Markets

Appili Therapeutics closes private placement

Closely-held Appili Therapeutics raised $3,062,000 in a private placement, bringing the total equity raised since its seed round in March 2016 to $7.5-million. The private placement includes investments from new and...

October 23, 2017
Aurinia Pharmaceuticals
Markets

Leerink ups Aurinia price target to $14

Leerink raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $14 from $10 after the company’s R&D day in New York last Friday. The stock closed at $6.15 on Oct. 20. Analyst Joseph Schwartz writes...

October 23, 2017
Nightstar Therapeutics
Markets

Leerink starts Nightstar at OP

Leerink initiated coverage of Nightstar Therapeutics (NASDAQ:NITE) with an “outperform” rating and $25 price target. The stock closed at $19 on Oct. 20. Nightstar is harnessing the potentially curative properties of...

October 23, 2017
Gemphire Logo
Markets

Roth starts Gemphire at buy

Roth Capital Markets launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and 12-month price target of $30. The stock closed at $9.54 on Oct. 18. “Our rating on Gemphire is driven by our...

October 19, 2017